Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Chubb
Colorcon
AstraZeneca
Express Scripts
Teva
Mallinckrodt
McKinsey
Johnson and Johnson

Generated: October 19, 2018

DrugPatentWatch Database Preview

Eli Lilly Co Company Profile

« Back to Dashboard

What is the competitive landscape for ELI LILLY CO, and when can generic versions of ELI LILLY CO drugs launch?

ELI LILLY CO has two approved drugs.

There are four US patents protecting ELI LILLY CO drugs.

Summary for Eli Lilly Co
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 1

Drugs and US Patents for Eli Lilly Co

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 RX Yes Yes 6,169,084 ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 AB2 RX Yes Yes 6,821,975*PED ➤ Sign Up Y ➤ Sign Up
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 AB2 RX Yes Yes 5,859,006*PED ➤ Sign Up ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 RX Yes No 6,169,084 ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 AB2 RX Yes Yes 7,182,958*PED ➤ Sign Up Y ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 RX Yes No 6,169,084 ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Eli Lilly Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 5,229,382*PED ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 5,229,382*PED ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 5,229,382*PED ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 6,169,084 ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 6,169,084 ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 6,169,084 ➤ Sign Up
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 5,859,006*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ELI LILLY CO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-10-15

Supplementary Protection Certificates for Eli Lilly Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0012 Belgium ➤ Sign Up PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
2003001,C0740668 Lithuania ➤ Sign Up PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
017 Luxembourg ➤ Sign Up
C0017 France ➤ Sign Up PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
081 Luxembourg ➤ Sign Up PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
C004/2003 Ireland ➤ Sign Up SPC004/2003, 20040610, EXPIRES: 20171111
C/GB96/058 United Kingdom ➤ Sign Up PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
McKinsey
Colorcon
Chubb
Boehringer Ingelheim
Julphar
Harvard Business School
McKesson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.